Learning Tracks

Last year’s launch of the first biosimilar of Humira (adalimumab) signified a major opportunity to increase patient access to, and lower the costs of, one of the bestselling drugs in the U.S. A year later—and despite competition from multiple lower-cost, FDA approved biosimilar versions – many commercial, employer and government payers and their PBMs have been slow to adopt these medications.   This panel examines the state of the Humira biosimilar market, recent evolution in the market, and shares lessons learned from current coverage, utilization management and dispensing practices for these medicines.